![]() ![]() ![]() The executive team will discuss its strategy for expanding its current billion-dollar franchises in dermatology and pet parasiticides, and new expectations for its osteoarthritis pain franchise to reach more than $1 billion in peak sales. Zoetis sees long-term sustainable growth driven by new products and lifecycle innovations for companion animals and livestock. Investing in capabilities and innovation that differentiate Zoetis.Ĭontinuing to create value for shareholders through revenue growth, strategic investments, margin expansion and capital return. ET today at the New York Stock Exchange, where the company will dive into its compelling growth ambitions, its innovative and robust R&D pipeline and its financial roadmap to continue delivering shareholder value, as it Shapes Animal Health for the Next Decade.ĭuring today’s presentations, Chief Executive Officer Kristin Peck, Chief Financial Officer Wetteny Joseph, President of Research & Development Robert Polzer, Ph.D., and other members of the Zoetis executive team will outline the company’s plans to deliver on its ambitions by:īuilding on its leadership in Animal Health to shape and expand the future of animal care.ĭelivering growth in a dynamic and resilient industry by innovating and growing faster than the market.ĭriving its next phase of game-changing franchises through internal R&D and business development. (NYSE:ZTS) is hosting an investor day at 9:00 a.m. PARSIPPANY, N.J.-(BUSINESS WIRE)- Zoetis Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |